TokenPost topic
Biotech
18 TokenPost stories are tagged Biotech. The newest appear first.
Latest Biotech stories
- Celldex Shares Slip 2% After Barzolvolimab Misses Goals in Atopic Dermatitis Trial
A phase 2 atopic dermatitis study of barzolvolimab missed its primary and secondary endpoints. Celldex shares fell about 2% in after-hours trading Thursday, Nov. 19.
· Business
- Exagen Maintains 2026 Revenue Outlook at $72 Million to $75 Million
Its myositis offering remains on track for an early 2027 launch.
· Business
- Aprea’s Q3 2026 Net Loss Widens to $4.81 Million as Trial Expands
Aprea projected that its current operating plan would cover cash needs for operating expenses and capital expenditures into the first quarter of 2028.
· Business
- Vir Biotechnology Narrows Third-Quarter Net Loss to $96.3 Million
The company’s loss per share was $0.57, compared with $1.17 a year earlier. Cash, cash equivalents and investments totaled about $901.3 million at Sept. 30.
· Business
- Geron Returns to Quarterly Profit as Rytelo Drives Q3 Revenue Growth
Rytelo revenue growth helped reverse a run of quarterly losses. Shares rose more than 10% in early premarket trading Nov. 4.
· Business
- Seaport Therapeutics Posts Third-Quarter GAAP Loss of $0.49 Per Share
The per-share loss beat estimates by $0.09.
· Business
- Oppenheimer Upgrades Incyte on Growth Beyond Jakafi’s 2029 Loss of Exclusivity
The firm set a $144 price target, about 23% above Incyte’s Oct. 29 close.
· Investing
- Pelthos Therapeutics Shares Fall About 35% After Castle Creek Merger Deal
The reported share price was $10.79. The proposed combination would add cell and gene therapies for serious skin diseases to Pelthos’ portfolio.
· Business
- Aspen Neuroscience Prices IPO at $15 a Share in 9.375 Million-Share Offering
The offering is expected to generate about $140.6 million in gross proceeds. Underwriters have 30 days to buy up to 1,406,250 additional shares.
· Business
- First Tracks Biotherapeutics Targets About $200 Million in Placement
The company agreed to sell about 6.11 million common shares at $32.75 each to institutional investors.
· Business
- BioNTech Shares Fall 6% After BNT113 Trial Misses Key Endpoint
The Phase 2/3 trial did not meet one of its dual primary endpoints, progression-free survival.
· Investing
- Bristol Myers Squibb Shares Rise After Two Late-Stage Trials Deliver Results
The ALOFT-IPF trial of admilparant in adults with idiopathic pulmonary fibrosis met its primary endpoint.
· Business
- Editas Wins Australia Clearance as Wells Fargo Upgrades Rating
Australian authorities cleared a Phase 1/2 gene-editing trial, while Wells Fargo moved its Editas rating from Equal Weight to Overweight.
· Business
- Sunshine Biopharma Announces $6 Million Public Offering Pricing
The offering includes 10.9 million common units, with expected gross proceeds of about $6 million.
· Business
- X4 Pharmaceuticals Enters $150 Million Senior Secured Loan Facility
The agreement with K2 HealthVentures replaces X4’s previous loan facility and includes an $80 million tranche funded at closing.
· Business
- Ascendis Pharma Reports Strong Phase 3 Durability Data for Yorvipath
Ascendis Pharma reported long-term Phase 3 data showing Yorvipath sustained biochemical control and reduced supplement reliance in hypoparathyroidism patients over 3.5 years.
· Business
- Genmab Highlights Epcoritamab Expansion, Advances AI-Driven Oncology Strategy
Genmab showcased epcoritamab’s expanded potential across lymphomas and unveiled AI-driven R&D initiatives at major oncology conferences to support pipeline growth.
· Business
- Incyte Reports Positive Phase 3 Data for Tafasitamab Combo in High-Risk Lymphoma
Incyte announced Phase 3 results showing its tafasitamab plus lenalidomide regimen significantly improved progression-free survival in high-risk lymphoma patients.
· Business